Research
Origin House founder sets $1 million fundraising target for medical cannabis research, care
Marc Lustig, chairman, and CEO of Origin House–a cannabis products and brands Firm Working across key markets in the U.S. and Canada–reports the fundraising Target for Its Lustig Family Medical Cannabis Research and Care Fund of the Cedars Cancer Foundation will be Declared to $1 million.
Having attained the initial aim of $250,000, Lustig claims that the new purpose is to increase the fund to $1 million within the next four decades, notes that a statement from Cedars Cancer Foundation, which contributes philanthropic initiatives which encourage innovation and excellence in clinical care, research, education, and supportive care providers.
A first-of-its-kind in Canada, a”medical cannabis treatment pilot project was first started in January 2018 with assistance from the Cedars Cancer Foundation and the Rossy Cancer Network’s Quality Improvement Initiatives Fund,” the press release states. Among other items, the fund supports the medical cannabis program in the McGill University Health Centre (MUHC).
“Evidence suggests that cannabis has a valuable role to play in relieving patient suffering, but we will need to spend more in medical cannabis maintenance, training and research,” says McGill grad Lustig, ambitious Canadians to help enhance direction in encouraging and palliative care and encourage healthcare professionals and scientists working at the emerging area.
Also Read: New Zealand forms laws to make medical cannabis widely available
“More than 20,000 cancer patients take care of the MUHC and now we’re seeing an increased need for medical cannabis treatment,” states Dr. Antonio Vigano, manager of the center’s Cancer Rehabilitation Program, associate professor of oncology at McGill and a primary investigator in 2 clinical cannabis clinical trials.
“Medical cannabis can relieve the substantial side effects which accompany cancer, for example, loss of appetite, sleeplessness, and anxiety,” Dr. Vigano states.
“Our pilot job was enlightening, but enhancing accessibility, correcting form, dose and the frequency of cannabinoid remedies via a precision-medicine strategy, analyzing the long-term consequences and strengthening appropriate training for health care professionals are essential,” he continues.